| Sensitive periods of substance abuse: Early risk for the transition to dependence CJ Jordan, SL Andersen Developmental cognitive neuroscience 25, 29-44, 2017 | 442 | 2017 |
| Progress in brain cannabinoid CB2 receptor research: From genes to behavior CJ Jordan, ZX Xi Neuroscience & Biobehavioral Reviews 98, 208-220, 2019 | 176 | 2019 |
| Evolution of autism support and understanding via the World Wide Web CJ Jordan Intellectual and developmental disabilities 48 (3), 220-227, 2010 | 146 | 2010 |
| Understanding differences in neurotypical and autism spectrum special interests through internet forums CJ Jordan, CL Caldwell-Harris Intellectual and developmental disabilities 50 (5), 391-402, 2012 | 137 | 2012 |
| Discovery and development of varenicline for smoking cessation CJ Jordan, ZX Xi Expert opinion on drug discovery 13 (7), 671-683, 2018 | 92 | 2018 |
| Systemizing and special interests: Characterizing the continuum from neurotypical to autism spectrum disorder CL Caldwell-Harris, CJ Jordan Learning and Individual Differences 29, 98-105, 2014 | 85 | 2014 |
| Dissecting the role of GABA neurons in the VTA versus SNr in opioid reward E Galaj, X Han, H Shen, CJ Jordan, Y He, B Humburg, GH Bi, ZX Xi Journal of Neuroscience 40 (46), 8853-8869, 2020 | 77 | 2020 |
| The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents CJ Jordan, B Humburg, M Rice, GH Bi, ZB You, AB Shaik, J Cao, ... Neuropharmacology 158, 107597, 2019 | 67 | 2019 |
| Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine CJ Jordan, J Cao, AH Newman, ZX Xi Neuropharmacology 158, 107609, 2019 | 66 | 2019 |
| Perinatal marijuana use and the developing child LM Jansson, CJ Jordan, ML Velez Jama 320 (6), 545-546, 2018 | 58 | 2018 |
| CB2 receptor antibody signal specificity: correlations with the use of partial CB2-knockout mice and anti-rat CB2 receptor antibodies H Zhang, H Shen, CJ Jordan, Q Liu, EL Gardner, A Bonci, Z Xi Acta Pharmacologica Sinica 40 (3), 398-409, 2019 | 54 | 2019 |
| New drugs, old targets: tweaking the dopamine system to treat psychostimulant use disorders AH Newman, T Ku, CJ Jordan, A Bonifazi, ZX Xi Annual review of pharmacology and toxicology 61, 609-628, 2021 | 48 | 2021 |
| Cocaine-seeking behavior in a genetic model of attention-deficit/hyperactivity disorder following adolescent methylphenidate or atomoxetine treatments CJ Jordan, RC Harvey, BB Baskin, LP Dwoskin, KM Kantak Drug and alcohol dependence 140, 25-32, 2014 | 44 | 2014 |
| Adolescent atomoxetine treatment in a rodent model of ADHD: effects on cocaine self-administration and dopamine transporters in frontostriatal regions SS Somkuwar, CJ Jordan, KM Kantak, LP Dwoskin Neuropsychopharmacology 38 (13), 2588-2597, 2013 | 44 | 2013 |
| Cannabinoid CB1 receptor neutral antagonist AM4113 inhibits heroin self-administration without depressive side effects in rats X He, CJ Jordan, K Vemuri, G Bi, J Zhan, EL Gardner, A Makriyannis, ... Acta Pharmacologica Sinica 40 (3), 365-373, 2019 | 41 | 2019 |
| mGluR5 antagonism inhibits cocaine reinforcement and relapse by elevation of extracellular glutamate in the nucleus accumbens via a CB1 receptor mechanism X Li, XQ Peng, CJ Jordan, J Li, GH Bi, Y He, HJ Yang, HY Zhang, ... Scientific reports 8 (1), 3686, 2018 | 41 | 2018 |
| Dopamine, behavior, and addiction RA Wise, CJ Jordan Journal of biomedical science 28 (1), 83, 2021 | 40 | 2021 |
| Translating the atypical dopamine uptake inhibitor hypothesis toward therapeutics for treatment of psychostimulant use disorders AH Newman, J Cao, JD Keighron, CJ Jordan, GH Bi, Y Liang, ... Neuropsychopharmacology 44 (8), 1435-1444, 2019 | 38 | 2019 |
| Performance on a strategy set shifting task during adolescence in a genetic model of attention deficit/hyperactivity disorder: methylphenidate vs. atomoxetine treatments RC Harvey, CJ Jordan, DH Tassin, KR Moody, LP Dwoskin, KM Kantak Behavioural brain research 244, 38-47, 2013 | 38 | 2013 |
| Newly developed dopamine D3 receptor antagonists, R-VK4-40 and R-VK4-116, do not potentiate cardiovascular effects of cocaine or oxycodone in rats CJ Jordan, BA Humburg, EB Thorndike, AB Shaik, ZX Xi, MH Baumann, ... Journal of Pharmacology and Experimental Therapeutics 371 (3), 602-614, 2019 | 29 | 2019 |
